Vanda Pharmaceuticals Inc [VNDA] stock is trading at $4.62, down -3.75%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VNDA shares have gain 7.19% over the last week, with a monthly amount drifted -0.65%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vanda Pharmaceuticals Inc [NASDAQ: VNDA] stock has seen the most recent analyst activity on October 31, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $18. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on July 11, 2024, and set its price target to $11. On February 25, 2022, downgrade downgraded it’s rating to Hold and revised its price target to $12 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $22 on May 12, 2021. Citigroup downgraded its rating to a Neutral but $14 remained the price target by the analyst firm on January 14, 2021. Citigroup upgraded its rating to Buy for this stock on October 29, 2020, but kept the price target unchanged to $14. In a note dated June 09, 2020, Citigroup downgraded an Neutral rating on this stock but restated the target price of $14.
Vanda Pharmaceuticals Inc [VNDA] stock has fluctuated between $3.65 and $6.75 over the past year. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Vanda Pharmaceuticals Inc [NASDAQ: VNDA] shares were valued at $4.62 at the most recent close of the market. An investor can expect a potential return of 138.1% based on the average VNDA price forecast.
Analyzing the VNDA fundamentals
Vanda Pharmaceuticals Inc [NASDAQ:VNDA] reported sales of 190.86M for the trailing twelve months, which represents a growth of 22.76%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.09%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.03 and Total Capital is -0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.51 points at the first support level, and at 4.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.77, and for the 2nd resistance point, it is at 4.93.
Ratios To Look Out For
For context, Vanda Pharmaceuticals Inc’s Current Ratio is 4.85. In addition, the Quick Ratio stands at 4.84 and the Cash Ratio stands at 1.13. Considering the valuation of this stock, the price to sales ratio is 1.41, the price to book ratio is 0.50.
Transactions by insiders
Recent insider trading involved Mitchell Stephen Ray, Director, that happened on Nov 14 ’24 when 5000.0 shares were sold. Director, Mitchell Stephen Ray completed a deal on Nov 14 ’24 to buy 5000.0 shares. Meanwhile, SVP, CFO & Treasurer Moran Kevin Patrick sold 2251.0 shares on Jul 29 ’24.
